Skip to content
Screener

Royalty Pharma RPRX Q2 2025 earnings

Reported August 6, 2025 · Before market open

Revenue$578.7MMiss by $94.3M
EPS$1.14Beat by $0.11
Revenue estimate$673.0M
EPS estimate$1.03

Next report

Nov 4, 2026 (in 2 months)
Revenue estimate$877.4M
EPS estimate$1.16

Financials

Q2 2025

Income statement

See full
Revenue$578.7M+7.7%
Operating income$209.8M-22.2%
Net income$32.2M-68.5%
EPS (diluted)$0.07-69.6%

Balance sheet

See full
Cash & equivalents$631.9M-64.2%
Total debt$8.0B+5.5%
Total equity$9.5B-2.6%
Total assets$18.3B+3.8%

Cash flow

See full
Operating cash flow$364.0M-44.7%

Valuation & ratios

Valuation

as of 06/30/25
See full
Market cap$15.23B+27.7%
Enterprise value$22.62B+27.4%
P/E14.9×-2.8×
P/S6.6×+1.3×

Profitability

See full
Operating margin79.8%+36.9pp
Net margin44.4%+14.3pp

Returns & leverage

See full
Return on equity10.6%+3.8pp
Debt / equity0.8×+0.1×
Current ratio1.3×-8.1×

FAQ

When did Royalty Pharma report Q2 2025 earnings?
Royalty Pharma (RPRX) reported Q2 2025 earnings on August 6, 2025 before market open.
What were Royalty Pharma's Q2 2025 revenue and EPS?
Royalty Pharma reported revenue of $578.7M and eps of $1.14 for Q2 2025.
Did Royalty Pharma beat estimates in Q2 2025?
Revenue missed the consensus estimate of $673.0M by $94.3M. EPS beat the consensus estimate of $1.03 by $0.11.
How did Royalty Pharma's Q2 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 7.7% from $537.3M a year earlier and eps grew 18.7% from $0.96.
Where can I find Royalty Pharma's Q2 2025 SEC filings?
You can read the 8-K earnings release (0001193125-25-173988) and the 10-Q periodic report (0001802768-25-000095) directly on SEC EDGAR. The filing index links above go to sec.gov.